27-Aug-2026
Globe Newswire (Tue, 18-Aug 7:30 AM ET)
Helus Pharma Advances Late-Stage Trials and Strengthens Cash Position Amid Key Leadership Changes
Market Chameleon (Fri, 14-Aug 4:53 AM ET)
Helus Pharma Reports First Quarter Fiscal 2027 Financial Results and Recent Business Highlights
Globe Newswire (Fri, 14-Aug 7:28 AM ET)
Helus Pharma to Participate at the Canaccord Genuity 46th Annual Growth Conference in Boston
Globe Newswire (Mon, 10-Aug 12:00 PM ET)
Globe Newswire (Wed, 5-Aug 10:25 AM ET)
Helus Pharma Appoints Michael Halstead as Chief Executive Officer
Globe Newswire (Mon, 3-Aug 7:40 AM ET)
Market Chameleon (Tue, 21-Jul 4:14 AM ET)
Globe Newswire (Tue, 21-Jul 7:50 AM ET)
Globe Newswire (Tue, 30-Jun 9:00 AM ET)
Helus Pharma Reports Recent Business Highlights and Fiscal Year 2026 Financial Results
Globe Newswire (Mon, 29-Jun 7:40 AM ET)
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.
Helus Pharma trades on the NASDAQ stock market under the symbol HELP.
As of August 27, 2026, HELP stock price declined to $13.24 with 837,994 million shares trading.
HELP has a beta of 2.14, meaning it tends to be more sensitive to market movements. HELP has a correlation of 0.09 to the broad based SPY ETF.
HELP has a market cap of $967.32 million. This is considered a Small Cap stock.
The top ETF exchange traded funds that HELP belongs to (by Net Assets): PSIL, QQQS.
HELP support price is $12.83 and resistance is $14.43 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that HELP shares will trade within this expected range on the day.
